Clinical Report: Exploring Multi-Omics Approaches to Tumor-Associated Macrophages

Overview

This editorial discusses the role of tumor-associated macrophages (TAMs) in cancer immunotherapy, emphasizing their heterogeneity and plasticity as revealed by multi-omics approaches.

Background

Tumor-associated macrophages are critical components of the tumor microenvironment, influencing cancer progression and therapeutic responses. Understanding their diverse functions and interactions within the TME is essential for developing effective immunotherapies. Recent advancements in multi-omics technologies provide deeper insights into TAM biology, paving the way for targeted therapeutic strategies.

Data Highlights

No numerical data provided in the source material.

Key Findings

• High-resolution multi-omics approaches reveal significant heterogeneity among TAM populations.
• TAMs play a pivotal role in promoting tumor progression and therapeutic resistance across various malignancies.
• Machine-learning integration of multi-omics datasets has led to the development of prognostic models based on TAM characteristics.
• Specific TAM subsets are associated with immune evasion and poor responses to immunotherapy.
• Novel therapeutic targets and strategies are emerging from the study of TAM activation and function.

Clinical Implications

Characterizing TAMs within the tumor microenvironment is important for enhancing the efficacy of immunotherapies.

Conclusion

The exploration of TAMs through multi-omics approaches offers promising insights that could significantly impact cancer immunotherapy strategies.

Related Resources & Content

1. Frontiers in Immunology, Editorial: Metabolic Reprogramming and Cancer Immunity: Advancements in Precision Immunotherapy, 2026 -- Title
2. Frontiers in Immunology, Modulating the Immune Response in Gastric Cancer: Insights into Macrophage Polarization and Immunotherapeutic Approaches, 2026 -- Title
3. Frontiers in Immunology, Editorial: The role of immune and stromal mediators in the formation of pre-metastatic and metastatic niches: the gateway to metastasis, 2026 -- Title
4. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1 | Journal of Clinical Oncology, 2026 -- Title
5. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols - PMC, 2025 -- Title
6. Frontiers in Immunology — The Immune Landscape of Melanoma Microenvironmental Crosstalk
7. Spatial multi-omics analyses of the tumor immune microenvironment: advances and novel therapeutic avenues | Molecular Cancer
8. Pan-cancer, multi-omic correlates of survival transcending tumor lineage across 11,019 patients reveal targets and pathways
9. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1 | Journal of Clinical Oncology
10. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols - PMC
11. Prognostic value of CD163+ macrophages in solid tumor malignancies: A scoping review - ScienceDirect
12. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments | Signal Transduction and Targeted Therapy
13. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial | Nature Medicine
14. Frontiers | Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances
15. EudraCT Number 2018-000339-28 - Clinical trial results - EU Clinical Trials Register
16. TREM2-mediated regulation of myeloid cells in the tumor microenvironment: new insights and therapeutic prospects | npj Precision Oncology